Inventory modeling for active pharmaceutical ingredient supply chains
Thesis: M.B.A., Massachusetts Institute of Technology, Sloan School of Management, in conjunction with the Leaders for Global Operations Program at MIT, May, 2020 === Thesis: S.M., Massachusetts Institute of Technology, Department of Civil and Environmental Engineering, in conjunction with the Leade...
Main Author: | |
---|---|
Other Authors: | |
Format: | Others |
Language: | English |
Published: |
Massachusetts Institute of Technology
2020
|
Subjects: | |
Online Access: | https://hdl.handle.net/1721.1/126946 |
id |
ndltd-MIT-oai-dspace.mit.edu-1721.1-126946 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-MIT-oai-dspace.mit.edu-1721.1-1269462020-09-06T06:48:49Z Inventory modeling for active pharmaceutical ingredient supply chains Bazerghi, Audrey. Thomas Roemer and David Simchi-Levi. Sloan School of Management. Massachusetts Institute of Technology. Department of Civil and Environmental Engineering. Leaders for Global Operations Program. Sloan School of Management Massachusetts Institute of Technology. Department of Civil and Environmental Engineering Leaders for Global Operations Program Sloan School of Management. Civil and Environmental Engineering. Leaders for Global Operations Program. Thesis: M.B.A., Massachusetts Institute of Technology, Sloan School of Management, in conjunction with the Leaders for Global Operations Program at MIT, May, 2020 Thesis: S.M., Massachusetts Institute of Technology, Department of Civil and Environmental Engineering, in conjunction with the Leaders for Global Operations Program at MIT, May, 2020 Cataloged from the official PDF of thesis. Includes bibliographical references (pages 66-68). Pharmaceutical companies traditionally manufactured drugs in-house, and have only recently been increasingly outsourcing production to contract manufacturing organizations (CMOs). In this work, we use inventory modeling to explore the trade-off between the attractive purchase price and the hidden costs of outsourcing for two active pharmaceutical ingredient (API) supply chains at AstraZeneca (AZ). We assess the inventory levels recommended by a base stock policy with deterministic purchase order lead times at each contracted stage of the supply chains. The single-echelon calculations reveal that safety stock levels are not systematically inflated at individual stages. The current inventory costs and service levels vary widely across products studied, as performance is hard to track over long periods of time and different inventory types. However, we demonstrate with a multi-echelon inventory optimization that a fully integrated API supply chain would yield savings compared to a purely external chain. Today, AZ's organizational processes allow it to partially coordinate with CMOs and capture up to 60 % of the value left on the table by not being able to optimize the full chain due to outsourcing. We propose using cost premium frontiers to prioritize further improvements at strategic outsourced nodes and align incentives. Partnering with CMOs to shorten lead times and increase flexibility is set to become a key advantage in a changing pharmaceutical environment with exacerbated volatility. by Audrey Bazerghi. M.B.A. S.M. M.B.A. Massachusetts Institute of Technology, Sloan School of Management S.M. Massachusetts Institute of Technology, Department of Civil and Environmental Engineering 2020-09-03T16:43:06Z 2020-09-03T16:43:06Z 2020 2020 Thesis https://hdl.handle.net/1721.1/126946 1191622448 eng MIT theses may be protected by copyright. Please reuse MIT thesis content according to the MIT Libraries Permissions Policy, which is available through the URL provided. http://dspace.mit.edu/handle/1721.1/7582 68 pages application/pdf Massachusetts Institute of Technology |
collection |
NDLTD |
language |
English |
format |
Others
|
sources |
NDLTD |
topic |
Sloan School of Management. Civil and Environmental Engineering. Leaders for Global Operations Program. |
spellingShingle |
Sloan School of Management. Civil and Environmental Engineering. Leaders for Global Operations Program. Bazerghi, Audrey. Inventory modeling for active pharmaceutical ingredient supply chains |
description |
Thesis: M.B.A., Massachusetts Institute of Technology, Sloan School of Management, in conjunction with the Leaders for Global Operations Program at MIT, May, 2020 === Thesis: S.M., Massachusetts Institute of Technology, Department of Civil and Environmental Engineering, in conjunction with the Leaders for Global Operations Program at MIT, May, 2020 === Cataloged from the official PDF of thesis. === Includes bibliographical references (pages 66-68). === Pharmaceutical companies traditionally manufactured drugs in-house, and have only recently been increasingly outsourcing production to contract manufacturing organizations (CMOs). In this work, we use inventory modeling to explore the trade-off between the attractive purchase price and the hidden costs of outsourcing for two active pharmaceutical ingredient (API) supply chains at AstraZeneca (AZ). We assess the inventory levels recommended by a base stock policy with deterministic purchase order lead times at each contracted stage of the supply chains. The single-echelon calculations reveal that safety stock levels are not systematically inflated at individual stages. The current inventory costs and service levels vary widely across products studied, as performance is hard to track over long periods of time and different inventory types. However, we demonstrate with a multi-echelon inventory optimization that a fully integrated API supply chain would yield savings compared to a purely external chain. Today, AZ's organizational processes allow it to partially coordinate with CMOs and capture up to 60 % of the value left on the table by not being able to optimize the full chain due to outsourcing. We propose using cost premium frontiers to prioritize further improvements at strategic outsourced nodes and align incentives. Partnering with CMOs to shorten lead times and increase flexibility is set to become a key advantage in a changing pharmaceutical environment with exacerbated volatility. === by Audrey Bazerghi. === M.B.A. === S.M. === M.B.A. Massachusetts Institute of Technology, Sloan School of Management === S.M. Massachusetts Institute of Technology, Department of Civil and Environmental Engineering |
author2 |
Thomas Roemer and David Simchi-Levi. |
author_facet |
Thomas Roemer and David Simchi-Levi. Bazerghi, Audrey. |
author |
Bazerghi, Audrey. |
author_sort |
Bazerghi, Audrey. |
title |
Inventory modeling for active pharmaceutical ingredient supply chains |
title_short |
Inventory modeling for active pharmaceutical ingredient supply chains |
title_full |
Inventory modeling for active pharmaceutical ingredient supply chains |
title_fullStr |
Inventory modeling for active pharmaceutical ingredient supply chains |
title_full_unstemmed |
Inventory modeling for active pharmaceutical ingredient supply chains |
title_sort |
inventory modeling for active pharmaceutical ingredient supply chains |
publisher |
Massachusetts Institute of Technology |
publishDate |
2020 |
url |
https://hdl.handle.net/1721.1/126946 |
work_keys_str_mv |
AT bazerghiaudrey inventorymodelingforactivepharmaceuticalingredientsupplychains |
_version_ |
1719339320651808768 |